Benchmark Reiterates Buy Rating on Humacyte (HUMA)

March 7, 2025 9:29 AM UTC Send to a Friend
Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $17.00 price target on Humacyte (NASDAQ: HUMA).The analyst commented, "Humacyte ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login